This tech startup’s new genetic engineering intern is working on a novel drug for cancer

A new bioengineering intern at a Silicon Valley biotech is working to create a novel cancer drug using a technique called gene editing.

In a recent episode of Recode with Kara Swisher, the intern was introduced to a project that could lead to a better cancer drug than current treatments.

The intern, who will not be named because she is not authorized to speak publicly, was a member of the Biomedical Engineering and Bioengineering (BEB) team, which worked on a prototype of a drug that was created using the gene editing technology.

Her research is being funded by the National Institutes of Health, and she has been using her internship to test a variety of different gene editing approaches.

It’s a promising development, because it shows the potential of genetic engineering for medicine and innovation, said the intern.

But the problem is that the technology has been around for a long time and is still relatively new.

The technology is still in its infancy, and the researchers behind it are trying to figure out how to integrate it into a clinical trial.

So, there’s no way to tell whether the new gene editing system will be useful, said Swisher.

The process of creating a drug by gene editing involves using a genetic material to modify the DNA of a cell or organ.

Then, a virus or bacteria injects the new DNA into that cell or cell organ.

When that process is complete, the gene will be altered in the cell.

The BEB team’s new drug, called Phe-A, has been shown to work by inhibiting the production of a protein that is a key part of a cellular signaling molecule called the receptor.

The receptor acts like a gate to stop a cell from making new proteins.

In the future, Phe would be tested on cancer patients to see if it can be used to treat them as well.